ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GRFS vs MIRM // ENTERPRISE SCALE & MARKET CAP

Grifols S.A. (NASDAQ) VS. Mirum Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GRFS 2 — MIRM 0
▲ ENTERPRISE SCALE & MARKET CAP LEADER: GRFS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRFS VS. MIRM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GRFS MIRM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -3.90% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.98% — TIE /fcf-yield <GO>
Operating Margin — -4.20% — TIE /operating-margins <GO>
Net Profit Margin — -4.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 54.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.29 — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 8/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.8 48.4 +18.40 GRFS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.99 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 32.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $5.57B $5.52B $50.0M GRFS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GRFS REV MIRM REV GRFS GROSS % MIRM GROSS % GRFS FCF MIRM FCF
FY 2025 — $521.3M — — — $54.9M
FY 2024 — $336.9M — — — $9.3M
FY 2023 — $186.4M — — — -$79.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRFS // BETA —
MIRM // BETA 0.99